Alsaedi, N. G., Alselaimy, R. M., Alshamrani, A. A., AlAjmi, M., Khandekar, R., Al-Dhibi, H., & Al-Abdullah, A. A. (2021). Aflibercept versus Ranibizumab as a Second Line Therapy After Bevacizumab for Diabetic Macular Edema. Clin Ophthalmol.
Styl ChicagoAlsaedi, Nasser G., Ruba M. Alselaimy, Abdulaziz A. Alshamrani, Muhammed AlAjmi, Rajiv Khandekar, Hassan Al-Dhibi, a Abdulelah A. Al-Abdullah. "Aflibercept Versus Ranibizumab As a Second Line Therapy After Bevacizumab for Diabetic Macular Edema." Clin Ophthalmol 2021.
Citace podle MLAAlsaedi, Nasser G., et al. "Aflibercept Versus Ranibizumab As a Second Line Therapy After Bevacizumab for Diabetic Macular Edema." Clin Ophthalmol 2021.
Upozornění: Tyto citace jsou generovány automaticky. Nemusí být zcela správně podle citačních pravidel..